Answers are grounded in this paper and cite their sources.
Lipid nanoparticles (LNPs) are the most clinically advanced and efficient method for delivering messenger RNA (mRNA), with most studies focusing on cancer mRNA vaccines and prophylactic mRNA vaccines against infectious diseases.1 Recent developments in this field have prompted researchers to explore the applicability of this platform toward additional therapies, such as mRNA-encoded antibody therapy.2 Unlike conventional recombinant antibody therapy, which is considered time-consuming and labor intensive, mRNA-encoded antibody therapy is faster, simpler, and more scalable.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: